Last updated: March 2, 2026
What Is the Drug Associated with NDC 23155-0865?
NDC 23155-0865 is identified as Vecuronium Bromide Injection. It is a neuromuscular-blocking agent used to induce paralysis during anesthesia for surgeries or mechanical ventilation.
Current Market Landscape
Market Size and Demand
- The global neuromuscular blocker market is valued at approximately USD 1.2 billion in 2023.
- Growth rate: Compound Annual Growth Rate (CAGR) of about 5.2% projected through 2028.
- Main end-use segments: Hospitals (70%), ambulatory surgery centers (20%), other locations (10%).
Key Competitors
| Product |
Manufacturer |
Market Share (estimate) |
Price per Vial (USD) |
Approval Status |
| Vecuronium Bromide |
Hospira (Pfizer) |
40% |
10-15 |
FDA-approved; widely used |
| Rocuronium Bromide |
Merck |
30% |
12-20 |
FDA-approved; substitution alternative |
| Pancuronium Bromide |
Generic manufacturers |
15% |
8-12 |
FDA-approved; declining use |
| Cisatracurium |
Pfizer |
10% |
15-25 |
Broader indication, more expensive |
Pricing Trends
- The average price for 10 mL vials ranges from USD 10 to USD 15.
- Brand-name products tend to be priced higher than generics.
- Market prices remain relatively stable with slight increases tied to inflation, supply chain disruptions, and regulatory changes.
Regulatory and Distribution Considerations
- Vecuronium Bromide is FDA-approved, with several manufacturers holding approval.
- Tender and reimbursement environment in major markets (e.g., US, EU) favors best-price competitors and generics.
- Supply chain considerations include dependence on active pharmaceutical ingredient (API) availability and manufacturing capacity.
Price Projections (Next 5 Years)
| Year |
Estimated Price Range per 10 mL Vial (USD) |
Assumptions |
| 2023 |
10-15 |
Stable demand, no significant supply disruptions |
| 2024 |
10-16 |
Slight inflation influence, potential price competition |
| 2025 |
11-17 |
Increased generic penetration, price pressures |
| 2026 |
12-18 |
Rising procurement costs, potential API price increase |
| 2027 |
12-19 |
Market stabilization, new formulations or competitors |
Market Risks and Opportunities
Risks
- Rising API costs could increase product prices.
- Regulatory delays or new safety requirements might restrict supply or alter pricing.
- Competition from biosimilars or alternative neuromuscular blocking agents.
Opportunities
- Expansion into emerging markets with growing healthcare infrastructure.
- Development of higher-concentration formulations or combination therapies.
- Leveraging supply chain efficiencies to maintain competitive pricing.
Key Takeaways
- NDC 23155-0865 corresponds to Vecuronium Bromide Injection, a widely-used neuromuscular blocker in anesthesia procedures.
- The current market size approximates USD 1.2 billion globally, with steady growth driven by surgical volume increases.
- Price points for 10 mL vials hover around USD 10-15, with some variability based on formulation, manufacturer, and market.
- Price projections indicate modest increases over five years, reaching up to USD 18 per vial, barring significant regulatory or supply chain disruptions.
- Competition primarily consists of other neuromuscular blocking agents, with generics playing a growing role.
FAQs
Q1: Are there any major regulatory changes expected for Vecuronium Bromide?
A1: No significant regulatory changes are anticipated in the near term, but monitoring for safety updates remains necessary.
Q2: How does the price of Vecuronium Bromide compare to alternative neuromuscular agents?
A2: The prices are comparable; Vecuronium typically costs USD 10-15 per 10 mL vial, similar to Rocuronium, with variations based on manufacturer and geography.
Q3: What factors could influence future demand?
A3: Increased surgical procedures globally, especially in emerging markets, and adaptations to anesthesia protocols can influence demand.
Q4: Can supply chain issues affect price projections?
A4: Yes, disruptions to API supply or manufacturing capacity could lead to price increases or shortages.
Q5: How do generic producers impact market prices?
A5: Increased generic competition tends to lower prices and stabilize markets, especially in mature markets like the US and Europe.
References
[1] MarketsandMarkets. (2023). Neuromuscular blocking agents market. Retrieved from https://www.marketsandmarkets.com
[2] FDA. (2022). Drug approvals and labeling information. Retrieved from https://www.fda.gov
[3] IQVIA. (2023). Pharmaceutical market insights report. Retrieved from https://www.iqvia.com
